{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BAY+59-7939",
    "query": {
      "intervention": "BAY 59-7939"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 132,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BAY+59-7939&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-11T04:46:06.247Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03630055",
      "title": "Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Radial Artery Occlusion"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban 15 MG Oral Tablet [Xarelto]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ottawa Heart Institute Research Corporation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 930,
      "start_date": "2018-10-03",
      "completion_date": "2025-06-26",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-09-11T04:46:06.247Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03630055"
    },
    {
      "nct_id": "NCT04755283",
      "title": "Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atrial Fibrillation (AF)",
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Abelacimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Anthos Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 1287,
      "start_date": "2021-02-02",
      "completion_date": "2028-12-29",
      "has_results": true,
      "last_update_posted_date": "2025-11-06",
      "last_synced_at": "2026-09-11T04:46:06.247Z",
      "location_count": 28,
      "location_summary": "Huntsville, Alabama • Mobile, Alabama • Stamford, Connecticut + 25 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04755283"
    },
    {
      "nct_id": "NCT01145859",
      "title": "Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Venous Thrombosis",
        "Pediatrics"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Months to 18 Years"
      },
      "enrollment_count": 59,
      "start_date": "2010-11",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-08-06",
      "last_synced_at": "2026-09-11T04:46:06.247Z",
      "location_count": 16,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Orange, California + 11 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01145859"
    },
    {
      "nct_id": "NCT00559988",
      "title": "Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Atrial Flutter",
        "Stroke",
        "Embolism, Systemic Arterial",
        "Major Bleeding"
      ],
      "interventions": [
        {
          "name": "Home Monitoring Guided OAC",
          "type": "DRUG"
        },
        {
          "name": "Physician-Directed OAC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biotronik, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2718,
      "start_date": "2008-02",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2017-12-05",
      "last_synced_at": "2026-09-11T04:46:06.247Z",
      "location_count": 73,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 70 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00559988"
    },
    {
      "nct_id": "NCT03359876",
      "title": "Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Warfarin sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16000,
      "start_date": "2017-12-01",
      "completion_date": "2019-03-29",
      "has_results": false,
      "last_update_posted_date": "2019-12-11",
      "last_synced_at": "2026-09-11T04:46:06.247Z",
      "location_count": 1,
      "location_summary": "Whippany, New Jersey",
      "locations": [
        {
          "city": "Whippany",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03359876"
    },
    {
      "nct_id": "NCT03172910",
      "title": "Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ciraparantag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 69,
      "start_date": "2017-05-08",
      "completion_date": "2019-11-12",
      "has_results": true,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-09-11T04:46:06.247Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03172910"
    },
    {
      "nct_id": "NCT01877915",
      "title": "A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure",
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of care for heart failure and coronary artery disease",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 5081,
      "start_date": "2013-09-10",
      "completion_date": "2018-04-19",
      "has_results": true,
      "last_update_posted_date": "2019-05-10",
      "last_synced_at": "2026-09-11T04:46:06.247Z",
      "location_count": 115,
      "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 112 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01877915"
    },
    {
      "nct_id": "NCT02561923",
      "title": "A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Tranexamic acid",
          "type": "DRUG"
        },
        {
          "name": "Kcentra, a 4-factor PCC",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 158,
      "start_date": "2015-08-27",
      "completion_date": "2016-06-17",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-09-11T04:46:06.247Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02561923"
    },
    {
      "nct_id": "NCT04059679",
      "title": "Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Peripheral Artery Disease"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban 2.5 Mg Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Aspirin 81 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LifeBridge Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2020-01-30",
      "completion_date": "2021-08",
      "has_results": false,
      "last_update_posted_date": "2020-10-14",
      "last_synced_at": "2026-09-11T04:46:06.247Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04059679"
    },
    {
      "nct_id": "NCT04192916",
      "title": "Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "DOACs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 442,
      "start_date": "2019-09-01",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-09-11T04:46:06.247Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04192916"
    }
  ]
}